Your session is about to expire
What is Gocovri
AmantadineThe Generic name of this drug
Treatment SummaryAmantadine is a medication used to prevent and treat influenza A. It is also used to treat movement disorders such as extrapyramidal reactions and postherpetic neuralgia. Its effects on movement disorders are not fully understood, but it appears to increase dopamine levels and may block the uptake of dopamine in the brain.
Symmetrelis the brand name
Gocovri Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Symmetrel
Amantadine
1976
103
Approved as Treatment by the FDA
Amantadine, also called Symmetrel, is approved by the FDA for 8 uses like Parkinson's Disease and influenza A virus .Parkinson's Disease
Helps manage Parkinson's Disease (PD)
influenza A virus
Parkinsonism
Helps manage Parkinsonism
Pharmacotherapy
Used in combination with other therapies
prophylaxis of Influenza A virus infection
Dyskinesia
Used in combination with other therapies
Parkinson Disease
Used in combination with other therapies
Extrapyramidal Disorders
Effectiveness
How Gocovri Affects PatientsAmantadine is a drug used to treat both viral infections and Parkinson's disease. It is related to another drug called rimantadine. Scientists are still unsure exactly how it works, but it appears to increase the release of dopamine in the brain and does not have any anticholinergic effects. It is often prescribed along with L-DOPA when the effects of L-DOPA start to decrease.
How Gocovri works in the bodyThe exact way this drug works for Parkinson's is not known, but it appears to increase dopamine levels in the brain and stimulate norepinephrine. It also blocks a certain type of receptor called NMDA. Its antiviral effects are unrelated to these. The drug stops a viral protein called M2 from working, which is needed for a virus to enter a cell and start reproducing.
When to interrupt dosage
The dosage of Gocovri is contingent upon the diagnosed condition, such as influenza A virus, Restless Legs Syndrome (RLS) and Parkinson's Disease. The amount of dosage is subject to the mode of delivery (e.g. Capsule - Oral or Oral) specified in the table beneath.Condition
Dosage
Administration
Parkinson Disease
50.0 mg/mL, , 100.0 mg, 68.5 mg, 137.0 mg, 129.0 mg, 193.0 mg, 258.0 mg, 10.0 mg/mL, 1.0 mg/mg, 8.0 mg/mg, 322.0 mg, 161.0 mg
, Oral, Solution, Solution - Oral, Capsule, Capsule - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Syrup, Syrup - Oral, Topical, Kit, Kit - Topical, Tablet - Oral, Tablet, Capsule, coated pellets, Capsule, coated pellets - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, extended release, Tablet, extended release - Oral
Dyskinesia
50.0 mg/mL, , 100.0 mg, 68.5 mg, 137.0 mg, 129.0 mg, 193.0 mg, 258.0 mg, 10.0 mg/mL, 1.0 mg/mg, 8.0 mg/mg, 322.0 mg, 161.0 mg
, Oral, Solution, Solution - Oral, Capsule, Capsule - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Syrup, Syrup - Oral, Topical, Kit, Kit - Topical, Tablet - Oral, Tablet, Capsule, coated pellets, Capsule, coated pellets - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, extended release, Tablet, extended release - Oral
Parkinsonism
50.0 mg/mL, , 100.0 mg, 68.5 mg, 137.0 mg, 129.0 mg, 193.0 mg, 258.0 mg, 10.0 mg/mL, 1.0 mg/mg, 8.0 mg/mg, 322.0 mg, 161.0 mg
, Oral, Solution, Solution - Oral, Capsule, Capsule - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Syrup, Syrup - Oral, Topical, Kit, Kit - Topical, Tablet - Oral, Tablet, Capsule, coated pellets, Capsule, coated pellets - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, extended release, Tablet, extended release - Oral
Extrapyramidal Disorders
50.0 mg/mL, , 100.0 mg, 68.5 mg, 137.0 mg, 129.0 mg, 193.0 mg, 258.0 mg, 10.0 mg/mL, 1.0 mg/mg, 8.0 mg/mg, 322.0 mg, 161.0 mg
, Oral, Solution, Solution - Oral, Capsule, Capsule - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Syrup, Syrup - Oral, Topical, Kit, Kit - Topical, Tablet - Oral, Tablet, Capsule, coated pellets, Capsule, coated pellets - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, extended release, Tablet, extended release - Oral
prophylaxis of Influenza A virus infection
50.0 mg/mL, , 100.0 mg, 68.5 mg, 137.0 mg, 129.0 mg, 193.0 mg, 258.0 mg, 10.0 mg/mL, 1.0 mg/mg, 8.0 mg/mg, 322.0 mg, 161.0 mg
, Oral, Solution, Solution - Oral, Capsule, Capsule - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Syrup, Syrup - Oral, Topical, Kit, Kit - Topical, Tablet - Oral, Tablet, Capsule, coated pellets, Capsule, coated pellets - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, extended release, Tablet, extended release - Oral
influenza A virus
50.0 mg/mL, , 100.0 mg, 68.5 mg, 137.0 mg, 129.0 mg, 193.0 mg, 258.0 mg, 10.0 mg/mL, 1.0 mg/mg, 8.0 mg/mg, 322.0 mg, 161.0 mg
, Oral, Solution, Solution - Oral, Capsule, Capsule - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Syrup, Syrup - Oral, Topical, Kit, Kit - Topical, Tablet - Oral, Tablet, Capsule, coated pellets, Capsule, coated pellets - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, extended release, Tablet, extended release - Oral
Parkinson's Disease
50.0 mg/mL, , 100.0 mg, 68.5 mg, 137.0 mg, 129.0 mg, 193.0 mg, 258.0 mg, 10.0 mg/mL, 1.0 mg/mg, 8.0 mg/mg, 322.0 mg, 161.0 mg
, Oral, Solution, Solution - Oral, Capsule, Capsule - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Syrup, Syrup - Oral, Topical, Kit, Kit - Topical, Tablet - Oral, Tablet, Capsule, coated pellets, Capsule, coated pellets - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, extended release, Tablet, extended release - Oral
Pharmacotherapy
50.0 mg/mL, , 100.0 mg, 68.5 mg, 137.0 mg, 129.0 mg, 193.0 mg, 258.0 mg, 10.0 mg/mL, 1.0 mg/mg, 8.0 mg/mg, 322.0 mg, 161.0 mg
, Oral, Solution, Solution - Oral, Capsule, Capsule - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Syrup, Syrup - Oral, Topical, Kit, Kit - Topical, Tablet - Oral, Tablet, Capsule, coated pellets, Capsule, coated pellets - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, extended release, Tablet, extended release - Oral
Warnings
Gocovri has one contraindication and should be avoided in situations involving the conditions in the following table.Gocovri ContraindicationsCondition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Amantadine may interact with Pulse Frequency
Common Gocovri Drug Interactions
Drug Name
Risk Level
Description
Adenovirus type 7 vaccine live
Major
The therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Amantadine.
Anthrax vaccine
Major
The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Amantadine.
BCG vaccine
Major
The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Amantadine.
Bacillus calmette-guerin substrain connaught live antigen
Major
The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Amantadine.
Bacillus calmette-guerin substrain russian BCG-I live antigen
Major
The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Amantadine.
Gocovri Toxicity & Overdose RiskTaking too much amantadine can be deadly, with the lowest reported fatal dose being 2 grams. Other toxicity symptoms could include changes in heartbeat, fluid buildup in the lungs, decreased kidney function, and central nervous system issues such as insomnia, anxiety, confusion, hallucinations, and coma. Seizures may be worse for those with a history of them, and some patients experience a fever.
Gocovri Novel Uses: Which Conditions Have a Clinical Trial Featuring Gocovri?
340 active studies are investigating the potential of Gocovri to alleviate Parkinsonism post encephalitic, Parkinsonism and Chorea symptoms.Condition
Clinical Trials
Trial Phases
prophylaxis of Influenza A virus infection
0 Actively Recruiting
Pharmacotherapy
0 Actively Recruiting
Parkinson Disease
0 Actively Recruiting
influenza A virus
4 Actively Recruiting
Not Applicable
Parkinsonism
3 Actively Recruiting
Phase 4
Parkinson's Disease
46 Actively Recruiting
Phase 3, Not Applicable, Phase 1, Phase 2, Early Phase 1
Dyskinesia
1 Actively Recruiting
Phase 3
Extrapyramidal Disorders
0 Actively Recruiting
Gocovri Reviews: What are patients saying about Gocovri?
5Patient Review
8/30/2018 Gocovri has effectively stopped my constant diskynesia.
5Patient Review
6/12/2019 I've been on this treatment for 17 months and it's done a great job of reducing my dyskinesia. Additionally, it seems to make all of my other medications work better. I saw an overall improvement in health within just a few months of starting this medication.
5Patient Review
8/3/20183Patient Review
3/19/2020 This medication started working after about a week, but the side effects were really tough to deal with. I had dry eye that was so bad that I couldn't read, watch TV or drive because my eyes would constantly water. I also lost my appetite and suffered from nightmares. It took me a couple of days to recover after stopping the medication, but thankfully I'm almost back to normal now.
2.7Patient Review
6/23/2021 The hallucinations and difficulty walking began after just six days on this medication. Even a week after stopping the med, I'm still experiencing issues. This has been really tough on my husband who's gone from being fully independent to needing help with basic activities of daily living.
Patient Q&A Section about gocovri
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.Is amantadine the same as Gocovri?
"The document is discussing a new once-daily formulation of amantadine, Gocovri, which is designed to help with the symptoms of dyskinesia (a motor disorder)."
Answered by AI
Is Gocovri FDA approved?
"On August 24, 2017, the FDA approved Gocovri, an oral, extended-release drug by Adamas Pharmaceuticals for the treatment of dyskinesia in patients with Parkinson's disease who receive levodopa-based therapy, with or without concomitant dopaminergic medications."
Answered by AI
How long does it take Gocovri to work?
"The Gocovri brand of amantadine takes 4 days to reach a steady level in the body, after which it starts working to reduce involuntary body movements associated with Parkinson's disease, extrapyramidal symptoms and chorea."
Answered by AI
What is the drug Gocovri used for?
"GOCOVRI is a prescription medicine used to treat patients with dyskinesia or OFF episodes who are also taking levodopa therapy. This medication works by increasing the effects of dopamine in the brain."
Answered by AI